about
HSulf-1 modulates FGF2- and hypoxia-mediated migration and invasion of breast cancer cellsEffects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecanCD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patientsRole of KRAS let-7 LCS6 SNP in metastatic colorectal cancer patientsReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsPatterns of tumor response in canine and feline cancer patients treated with electrochemotherapy: preclinical data for the standardization of this treatment in pets and humans.Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialConcomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of lifeFatal thrombocytopenia and thrombocytopathia: an unusual onset of non-small cell lung cancer.Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour targetTumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancerGenetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy.The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients.New molecular targets in bone metastases.High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade.The antineoplastic treatment in the elderly.Liver cirrhosis after prolonged therapy with IFN-alpha plus interleukin-2 in a metastatic renal cancer long-term survivor.Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis surveyBone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?Human equilibrative nucleoside transporter 1 and carcinoma of the ampulla of Vater: expression differences in tumour histotypes.Classic Kaposi Sarcoma: to treat or not to treat?The antineoplastic role of bisphosphonates: from basic research to clinical evidence.Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer.Prognostic value of Bax, Bcl-2, p53, and TUNEL staining in patients with radically resected ampullary carcinoma.Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancer.Pazopanib and pancreatic toxicity: a case report.Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer: long-term results according to downstaging.Prognostic Relevance of Objective Response According to EASL Criteria and mRECIST Criteria in Hepatocellular Carcinoma Patients Treated with Loco-Regional Therapies: A Literature-Based Meta-Analysis.COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables.Bisphosphonate effects in cancer and inflammatory diseases: in vitro and in vivo modulation of cytokine activities.Deregulation of dicer and mir-155 expression in liposarcoma.Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study
P50
Q24338405-9C5AD9C1-DDA2-47A4-9057-443A07EB32BBQ27851573-DCD7665A-A198-40D8-ABE7-D5504D0F73E0Q28274019-5F111420-3E02-4D1A-8DB9-2424558E756AQ28286080-39389F00-D438-4353-8C1C-05A996B6B11DQ28294985-52C281F5-9FF0-423B-B4E9-C1DA39CFF989Q28740575-FF5E8774-6E13-4FC0-ACE0-8C994A1177ADQ31131796-3389F766-D516-4110-B1D6-69895A9C5D8FQ33242985-4F16E1EE-4D76-4A91-B738-F8B30576627FQ33270398-7BDAA453-9CAD-4E5D-85CC-17F3352D5CF2Q33348832-A42B504B-BC90-42AA-BF37-DFDC93332E3CQ33372501-4C7CC608-1284-401E-B72E-331019C5F6EFQ33389231-A5F97C70-5633-41DE-B5F0-E127501D013BQ33391296-235B45BD-586F-47D4-87FD-D068E8FCBF43Q33399656-90A654CC-5EFF-410B-9778-DB1F1446297BQ33404411-7F10C273-9235-4CFB-B74C-2D876965E4C6Q33503255-94803AE8-E9EA-4970-AC1F-CD2D5310F5A1Q33644262-A7CFA998-6A43-4103-AB0D-F59C7242540CQ33714950-1DEB4493-CF4F-4F08-A232-1CCA1C7ADCE5Q33982331-E930910F-56B4-4FB8-A25B-7DE810EB4710Q34024907-477415B3-D7DF-47B2-B9D3-D41A4FE9D64DQ34091419-4055F7A8-7F18-4F0D-92CA-5CB587F86EDFQ34574793-4FE7E4CC-3F0F-4E99-888F-3F3337C5CEC8Q34773438-6A361F6B-EDCB-4851-BC16-3749018F051EQ34774141-63957D18-A3E0-42CF-A14A-FCD65E43F1DDQ35064862-D8EA7C43-08A0-42EC-8B76-92B0ECCB6CCBQ35080143-9EA1EF45-3098-46F8-BC53-447596F47781Q35083485-42725443-E1CD-4BC7-B149-978326373A76Q35197256-C32817FF-8B1A-49C2-A78A-03DC088E1E19Q35401782-E15415F4-0255-4471-B488-2E2F4602CD8BQ35540836-CFB4FB96-2369-455D-8C67-A184DF5E5635Q35587652-752640F6-357F-4CD5-8810-15915B53EB80Q35588363-DDCF487B-E6A6-4582-AB67-D2237EA6B548Q35588677-46F11FEA-7591-4E43-AC83-80136A39A087Q35616735-6862B1A2-E5F0-466A-BE88-BE2D050D2B1DQ35681555-F71A4FD1-B1A7-49A3-9C78-2D225F285C92Q35731141-56BE315F-B00E-4017-B4D4-E810B37FF24EQ35769624-F6C34E5D-F29A-40C8-A6F7-208EA1F6004CQ35831541-0FD54064-A9FC-47BC-8566-BD4DD69B9083Q35833073-CF15F3E5-FE1D-49B0-B93D-AE8996190970Q35909766-532418EB-47DB-4DBC-9D31-EDD2F90968E7
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Bruno Vincenzi
@ast
Bruno Vincenzi
@en
Bruno Vincenzi
@es
Bruno Vincenzi
@nl
Bruno Vincenzi
@sl
type
label
Bruno Vincenzi
@ast
Bruno Vincenzi
@en
Bruno Vincenzi
@es
Bruno Vincenzi
@nl
Bruno Vincenzi
@sl
prefLabel
Bruno Vincenzi
@ast
Bruno Vincenzi
@en
Bruno Vincenzi
@es
Bruno Vincenzi
@nl
Bruno Vincenzi
@sl
P106
P21
P31
P496
0000-0001-8222-9025